Search alternatives:
significant changes » significant challenge (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
changes decrease » larger decrease (Expand Search), largest decrease (Expand Search), change increases (Expand Search)
significant changes » significant challenge (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
changes decrease » larger decrease (Expand Search), largest decrease (Expand Search), change increases (Expand Search)
-
501
-
502
Flow chart of sediment P fractionation procedure.
Published 2025“…The NH<sub>4</sub>Cl-Po and NaHCO<sub>3</sub>-Po concentrations in sediments showed the greatest decrease (accounting for 97.6% of total decrease) during the experiment. …”
-
503
-
504
-
505
Changes in foveal location after surgery.
Published 2025“…</p><p>Conclusions</p><p>The macular topography significantly changed after iERM removal; the fovea moved nasally, and the distance between the superior and inferior vascular arcades increased. …”
-
506
-
507
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
508
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
509
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
510
-
511
-
512
Predicted probability of infection symptoms due to forest cover for 2011 and 2016.
Published 2025Subjects: -
513
-
514
-
515
Cohort characteristics.
Published 2025“…Concomitantly, the lactate/pyruvate ratio significantly increased (12.81 + /- 0.90 vs 67.1 + /- 7.94; p < 0.0001) while the acetoacetate/β-hydroxybutyrate ratio significantly decreased (1.11 + /- 0.19 vs. 0.54 + /- 0.05 at 0 min; p = 0.0055). …”
-
516
-
517
-
518
-
519
-
520
Intercorrelation matrix of kindness, institutional identity, stress, and well-being.
Published 2024Subjects: